Cubist Systematic Strategies, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

$20.3 Billion
Q2 2025

A detailed history of Cubist Systematic Strategies, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 2,700 shares of MDGL stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,700

Previous 19,827 86.38%

Holding current value

$1.2 Million

Previous $6.57 Million 87.56%

% of portfolio

0.0%

Previous 0.04%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$272.79 - $355.88 $5.41 Million - $7.06 Million	19,827 New	19,827 $6.57 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $1.25 Million - $2.07 Million	7,291 Added 423.4%	9,013 $2.41 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $207,328 - $408,337	1,722 New	1,722 $398,000
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $1.55 Million - $2.06 Million	6,708 Added 56.37%	18,609 $4.51 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $72,286 - $367,116	1,238 Added 11.61%	11,901 $3.45 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $421,748 - $553,628	6,963 Added 188.19%	10,663 $693,000
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $127,746 - $220,540	-2,201 Reduced 37.3%	3,700 $265,000
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $611,604 - $1.11 Million	-10,943 Reduced 64.97%	5,901 $579,000
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $1.07 Million - $1.41 Million	14,824 Added 733.86%	16,844 $1.43 Million
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $2.01 Million - $2.69 Million	-25,644 Reduced 92.7%	2,020 $161,000
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $2.69 Million - $3.81 Million	27,664 New	27,664 $2.7 Million
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $1.66 Million - $1.91 Million	-15,281 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $898,970 - $1.09 Million	8,168 Added 114.83%	15,281 $1.7 Million
Q3 2020 Nov 16, 2020	BUY	$99.78 - $124.21 $395,428 - $492,244	3,963 Added 125.81%	7,113 $845,000
Q2 2020 Aug 14, 2020	BUY	$60.13 - $125.71 $45,097 - $94,282	750 Added 31.25%	3,150 $357,000
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $740,835 - $1.04 Million	-11,097 Reduced 82.22%	2,400 $160,000
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $539,729 - $758,874	6,404 Added 90.29%	13,497 $1.23 Million
Q3 2019 Nov 14, 2019	BUY	$84.4 - $106.53 $369,418 - $466,281	4,377 Added 161.16%	7,093 $612,000
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $111,907 - $174,990	1,228 Added 82.53%	2,716 $285,000
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $26,387 - $36,679	255 Added 20.68%	1,488 $186,000
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $71,361 - $162,301	-753 Reduced 37.92%	1,233 $139,000
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $411,697 - $596,415	1,986 New	1,986 $425,000
Q1 2018 May 15, 2018	SELL	$93.35 - $149.04 $123,875 - $197,776	-1,327 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$39.35 - $97.37 $52,217 - $129,209	1,327	1,327 $122,000

Others Institutions Holding MDGL

# of Institutions

356

Shares Held

23.2M

Call Options Held

738K

Put Options Held

473K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $7.58B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Madrigal Pharmaceuticals, Inc. Transaction History